Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials
Authors:
- M.M. GermaniMGM.M. Germani
- A. TaravellaATA. Taravella
- D. RossiniDRD. Rossini
- L. WeissLWL. Weiss
- F. MoranoFMF. Morano
- F. BergamoFBF. Bergamo
- V. StudialeVSV. Studiale
- A. StahlerASA. Stahler
- M. CarulloMCM. Carullo
- L. SalvatoreLSL. Salvatore
- K. HeinrichKHK. Heinrich
- A. PassardiA. Passardi
Open Access
Abstract
No abstract availableFunding Information
- Ministero dell'Istruzione e del Merito
This publication has 28 references indexed in Scilit:
- Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver MetastasesJAMA Oncology, 2026
- Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forwardeClinicalMedicine, 2024
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular featuresCancer Treatment Reviews, 2022
- Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal CancerJAMA Oncology, 2019
- Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastasesBritish Journal of Surgery, 2018
- Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal CancerJAMA Oncology, 2018
- The Strength of Association Between Surrogate End Points and Survival in OncologyJAMA Internal Medicine, 2015
- Estimating the correlation of bivariate failure times under censoringStatistics in Medicine, 2013
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803European Journal of Cancer, 2011